The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN170522     5-acetamido-2-hydroxy-benzoic acid

Synonyms: AG-C-05752, AG-F-74857, NSC-54183, Oprea1_150410, Oprea1_590376, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of N-Acetyl-5-aminosalicylic acid


High impact information on N-Acetyl-5-aminosalicylic acid


Biological context of N-Acetyl-5-aminosalicylic acid

  • An in vivo study shows that the labelled compound, administered to rats, is excreted isotopically unchanged to at least 97%, and that no significant deacetylation/acetylation mechanism exists for this metabolite N-acetyl-5-aminosalicylic acid of salicylazosulphapyridine [8].
  • Since 5-ASA can not be measured directly in the colon, the bioavailability was evaluated by studying the plasma concentration and cumulative urinary excretion (Ae) of its main metabolite N-acetyl-5-aminosalicylic acid (ac-5-ASA) [9].

Anatomical context of N-Acetyl-5-aminosalicylic acid


Analytical, diagnostic and therapeutic context of N-Acetyl-5-aminosalicylic acid


  1. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Lauritsen, K., Hansen, J., Ryde, M., Rask-Madsen, J. Gastroenterology (1984) [Pubmed]
  2. Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine. Bystrowska, B., Nowak, J., Brandys, J. Journal of pharmaceutical and biomedical analysis. (2000) [Pubmed]
  3. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Sandborn, W.J., Hanauer, S.B., Buch, A. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  4. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Hussain, F.N., Ajjan, R.A., Kapur, K., Moustafa, M., Riley, S.A. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  5. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Simmonds, N.J., Millar, A.D., Blake, D.R., Rampton, D.S. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  6. Intestinal metabolism and transport of 5-aminosalicylate. Zhou, S.Y., Fleisher, D., Pao, L.H., Li, C., Winward, B., Zimmermann, E.M. Drug Metab. Dispos. (1999) [Pubmed]
  7. Evaluation of biotransformation of sulphasalazine in the colon epithelial Caco-2 cells. Bat, B., Lodowska, J., Orchel, A., Parfiniewicz, B., Weglarz, L., Dzierzewicz, Z., Wilczok, T. Acta poloniae pharmaceutica. (2004) [Pubmed]
  8. A stable isotope method for the quantification of N-acetyl-5-aminosalicylic acid in plasma and urine. Fischer, C., Meese, C.O., Klotz, U. Biomed. Mass Spectrom. (1984) [Pubmed]
  9. Relative bioavailability of olsalazine from tablets and capsules: a drug targeted for local effect in the colon. Ryde, M., Huitfeldt, B., Pettersson, R. Biopharmaceutics & drug disposition. (1991) [Pubmed]
  10. Inhibitory effect of flavonoids on N-acetylation of 5-aminosalicylic acid in cultured rat hepatocytes. Mizoyama, Y., Takaki, H., Sugihara, N., Furuno, K. Biol. Pharm. Bull. (2004) [Pubmed]
  11. Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses. Knoll, U., Strauhs, P., Schusser, G., Ungemach, F.R. J. Vet. Pharmacol. Ther. (2002) [Pubmed]
WikiGenes - Universities